Handelsbanken Fonder AB Has $54.15 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Handelsbanken Fonder AB decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 136,185 shares of the biopharmaceutical company’s stock after selling 19,184 shares during the quarter. Handelsbanken Fonder AB’s holdings in Alnylam Pharmaceuticals were worth $54,154,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $32,000. Aster Capital Management DIFC Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $36,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ALNY. Barclays began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 5th. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Royal Bank Of Canada reduced their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Finally, Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $722,795.90. Following the transaction, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 21,255 shares of company stock worth $6,930,337. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $294.30 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $39.29 billion, a price-to-earnings ratio of 80.41 and a beta of 0.31. The firm’s fifty day moving average price is $312.56 and its two-hundred day moving average price is $362.08. Alnylam Pharmaceuticals, Inc. has a 1 year low of $284.19 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.